NCT07127315

Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy

A Prospective Study Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 100 (actual)
• Sponsor: Helwan University · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the benefits of gonadotropin-releasing hormone agonist administration during chemotherapy on preserving ovarian function and Fertility in Premenopausal breast cancer patients, as assessed by anti-mullerian hormone levels, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol (E2) levels.

Detailed description

The annually estimated number of females diagnosed with cancer is about 6.6 million, 10% of whom are premenopausal. To minimize the risk of ovarian dysfunction and infertility for these patients, ovarian reserve differs widely from one female to another, but it could be assessed by Ultrasound to reveal antral follicle count (AFC). Also, the hormonal levels of anti-Müllerian hormone (AMH), estradiol (E2), and follicle-stimulating hormone FSH are valuable indicators for fertility.

Conditions

• Gonadotropin Releasing Hormone Agonists
• Ovarian Function
• Premenopausal
• Breast Cancer
• Chemotherapy

Interventions

Type	Name	Description
DRUG	Gonadotropin-releasing hormone agonist	Patients received chemotherapy plus a gonadotropin-releasing hormone agonist.
DRUG	Chemotherapy	Patients received chemotherapy alone.

Timeline

• Start date: 2022-07-01
• Primary completion: 2024-06-01
• Completion: 2024-07-01
• First posted: 2025-08-17
• Last updated: 2025-08-17

Locations

1 site across 1 country: Egypt